Autoimmune/Cholestatic/Biliary Diseases News

BOSTON — Healio spoke with James L. Boyer, MD, FACEP, about interim results from the phase 2a INTEGRIS-PSC trial presented at The Liver Meeting, which showed bexotegrast reduced biomarkers of liver fibrosis vs. placebo.

BOSTON — Healio spoke with James L. Boyer, MD, FACEP, about research assessing the role of Claudin-1 in cholangiocarcinoma, which was presented at The Liver Meeting.

BOSTON — Patients with metabolic dysfunction-associated steatotic liver disease who underwent bariatric surgery lost less weight over 5 years than those without MASLD, according to research presented at The Liver Meeting.

BOSTON — After 52 weeks, elafibranor achieved biochemical response and improved symptoms of pruritus in patients with primary biliary cholangitis, according to late-breaking data presented at The Liver Meeting.

BOSTON — Healio spoke with James L. Boyer, MD, about phase 3 findings from the RESPONSE trial and the ELATIVE trial and presented at The Liver Meeting.

The FDA has granted fast track designation to Chemomab Therapeutics’ anti-CCL24 monoclonal antibody, CM-101, for the treatment of adults with primary sclerosing cholangitis, according to a manufacturer release.

BOSTON — In a Healio video exclusive, Pam Vig, PhD, reports late-breaking data that show Livmarli improved liver health and maintained symptom response over 2 years among pediatric patients with progressive familial cholestasis.

Although the use of robotic-assisted cholecystectomy increased 37-fold from 2010 to 2019, the procedure was associated with significantly higher rates of bile duct injury compared with laparoscopic cholecystectomy, according to research.

International Primary Biliary Cholangitis Day, celebrated on September 10, aspires to raise awareness of the challenges that patients with this rare liver disease face and how their stories can help advance diagnosis, treatment and care.

The FDA granted orphan drug designation for KB408 for the treatment of alpha-1 antitrypsin deficiency, according to a press release from Krystal Biotech.